Zobrazeno 1 - 4
of 4
pro vyhledávání: '"329"'
Autor:
Binal N. Shah, Rasha Raslan, Jin Han, Michel Gowhari, Andrew Srisuwananukorn, Xu Zhang, Robert E. Molokie, Santosh L. Saraf, Victor R. Gordeuk
Publikováno v:
Blood Adv
Sickle cell disease (SCD) is an inherited red blood cell disorder that leads to vaso-occlusion, endothelial damage, and activation of pro-coagulant pathways. Recent studies have demonstrated that thrombotic episodes occur at a 3- to 100-fold higher r
Autor:
Wilson I. Gonsalves, Ronald S. Go, Nidhi Tandon, John A. Lust, Amie Fonder, Surbhi Sidana, Angela Dispenzieri, Nelson Leung, Steven R. Zeldenrust, Suzanne R. Hayman, Miriam Hobbs, Shaji Kumar, Martha Q. Lacy, Robert A. Kyle, Stephen J. Russell, Yi L. Hwa, Francis K. Buadi, S. Vincent Rajkumar, David Dingli, Morie A. Gertz, Prashant Kapoor
Publikováno v:
Blood. 128:4627-4627
Introduction High dose chemotherapy and autologous stem cell transplantation (ASCT) is an effective therapy for eligible patients with newly diagnosed systemic AL amyloidosis. Dose attenuated melphalan is used in patients with older age, renal dysfun
Autor:
Leslie A. Andritsos, Natarajan Muthusamy, Qiuhong Zhao, John C. Byrd, Jennifer A. Woyach, Heather Breidenbach, Jeffrey Jones, Amber Gordon, Meixiao Long, Nyla A. Heerema, Caitlin Coombes, Farrukh T. Awan, Amy S. Ruppert
Publikováno v:
Blood. 128:4372-4372
Chronic Lymphocytic Leukemia (CLL) has a varied clinical course; some patients experience a long survival and others succumb to disease in a short time. Clinical factors correlated with either time to first treatment (TFT) and/or overall survival inc
Autor:
Muneer H. Abidi, Andy I. Chen, Tamas Masszi, Auayporn Nadamanee, Veronika Bachanova, Naomi N. H. Hunder, Patrick J. Stiff, Simonetta Viviani, Anna Sureda, Angelo Michele Carella, Dirk Huebner, Jan Walewski, Emily K. Larsen, Jerzy Holowiecki, Craig H. Moskowitz, Dzhelil Osmanov, John W. Sweetenham, Edward Agura
Publikováno v:
Blood. 126:3172-3172
Introduction The AETHERA trial is a phase 3, randomized, placebo-controlled trial (ClinicalTrials.gov #NCT01100502), which evaluated whether post-ASCT consolidation treatment with brentuximab vedotin (BV) could prevent disease progression in Hodgkin